Global Radiopharmaceuticals in Nuclear Medicine
Global Radiopharmaceuticals in Nuclear Medicine

Radiopharmaceuticals in Nuclear Medicine Comprehensive Study by Type (Diagnostic Nuclear Medicine (PECT Radiopharmaceuticals, PET Radiopharmaceuticals), Therapeutic Nuclear Medicine (Alpha Emitters, Beta Emitters), Brachytherapy Isotopes (Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other)), Application (SPECT Applications (Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications), PET Applications (Oncology, Cardiology, Neurology, Other PET Applications), Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other)), End User (Hospitals, Research Institutes, Others) Players and Region - Global Market Outlook to 2026

Radiopharmaceuticals in Nuclear Medicine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Nov 2021 Edition 208 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Radiopharmaceuticals in Nuclear Medicine?
Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.

The market study is broken down by Type (Diagnostic Nuclear Medicine [PECT Radiopharmaceuticals, PET Radiopharmaceuticals], Therapeutic Nuclear Medicine [Alpha Emitters, Beta Emitters] and Brachytherapy Isotopes [Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other]), by Application (SPECT Applications [Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications], PET Applications [Oncology, Cardiology, Neurology, Other PET Applications] and Therapeutic Applications [Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other]) and major geographies with country level break-up.

Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Radiopharmaceuticals in Nuclear Medicine market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacıbaşı-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France) and NTP Radioisotopes (South Africa) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are JSC Isotope (Russia), NorthStar Medical Radioisotopes (United States), Eckert & Ziegler (Germany), IBA Molecular Imaging, Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Life Molecular Imaging, Cardinal Health, Inc., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, DuChemBio, Inc., Rotem Industries and Cambridge Isotope Laboratories, Inc..

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Radiopharmaceuticals in Nuclear Medicine market by Type, Application and Region.

On the basis of geography, the market of Radiopharmaceuticals in Nuclear Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Radiopharmaceuticals in Nuclear Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 31 May 2021, Curium has successfully completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its footprint in Europe for its broad portfolio of life-saving diagnostic solutions. This is the second acquisition of a positron-emission-tomography (PET) radiopharmaceutical business by Curium this year after the acquisition of M2i, a leading Irish PET player, earlier this year. As part of the transaction, some non-core businesses, including a portfolio of real estate properties, were divested to a group of entrepreneurs.
On 21st March 2021, GE Healthcare today unveiled StarGuide, a next-generation SPECT/CT system that uses the latest digital technologies to help clinicians improve patient outcomes in bone procedures, cardiology, neurology, oncology, and other medical specialties. The system’s cutting edge 12 CZT Digital Focus Detectors not only scan patients in 3D to provide more information to clinicians but are also optimized for Theranostic procedures, which combine the delivery of therapy to patients with diagnosis to monitor disease.


Market Trend
  • High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99

Market Drivers
  • Rising incidence as well as prevalence of target conditions
  • Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments

Opportunities
  • Use of radiopharmaceuticals in neurological applications

Restraints
  • Short half-life of radiopharmaceuticals

Challenges
  • Hospital budget cuts and high equipment costs


Analyst View
Coronavirus disease 2019 (COVID19) is an acute respiratory infectious disease caused by the coronavirus 2 (SARSCoV2) of the severe acute respiratory syndrome. COVID-19 was hardly unknown before the outbreak in Wuhan, China, in December 2019. In just a few weeks, it went from a regional catastrophe to a global epidemic. On March 11, 2020, the World Health Organization (WHO) proclaimed COVID-19 a pandemic. The COVID-19 pandemic has resulted in significant modifications in radiology department clinical operations around the world.

Key Target Audience
Radiopharmaceuticals in Nuclear Medicine Providers, Government Orgnization, Private Research Organization, Government Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacıbaşı-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France) and NTP Radioisotopes (South Africa) etc.

2. Can we have customized study for Radiopharmaceuticals in Nuclear Medicine Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Radiopharmaceuticals in Nuclear Medicine Market by 2026?
Analysts at AMA estimates Radiopharmaceuticals in Nuclear Medicine Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Type
  • Diagnostic Nuclear Medicine [PECT Radiopharmaceuticals, PET Radiopharmaceuticals]
  • Therapeutic Nuclear Medicine [Alpha Emitters, Beta Emitters]
  • Brachytherapy Isotopes [Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other]
By Application
  • SPECT Applications [Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications]
  • PET Applications [Oncology, Cardiology, Neurology, Other PET Applications]
  • Therapeutic Applications [Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other]
By End User
  • Hospitals
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising incidence as well as prevalence of target conditions
      • 3.2.2. Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments
    • 3.3. Market Challenges
      • 3.3.1. Hospital budget cuts and high equipment costs
    • 3.4. Market Trends
      • 3.4.1. High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiopharmaceuticals in Nuclear Medicine, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radiopharmaceuticals in Nuclear Medicine (Value)
      • 5.2.1. Global Radiopharmaceuticals in Nuclear Medicine by: Type (Value)
        • 5.2.1.1. Diagnostic Nuclear Medicine [PECT Radiopharmaceuticals, PET Radiopharmaceuticals]
        • 5.2.1.2. Therapeutic Nuclear Medicine [Alpha Emitters, Beta Emitters]
        • 5.2.1.3. Brachytherapy Isotopes [Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other]
      • 5.2.2. Global Radiopharmaceuticals in Nuclear Medicine by: Application (Value)
        • 5.2.2.1. SPECT Applications [Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications]
        • 5.2.2.2. PET Applications [Oncology, Cardiology, Neurology, Other PET Applications]
        • 5.2.2.3. Therapeutic Applications [Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other]
      • 5.2.3. Global Radiopharmaceuticals in Nuclear Medicine by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Research Institutes
        • 5.2.3.3. Others
      • 5.2.4. Global Radiopharmaceuticals in Nuclear Medicine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Radiopharmaceuticals in Nuclear Medicine (Price)
      • 5.3.1. Global Radiopharmaceuticals in Nuclear Medicine by: Type (Price)
  • 6. Radiopharmaceuticals in Nuclear Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cardinal Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE Healthcare (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Curium (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lantheus Medical Imaging (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bracco Imaging (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eczacıbaşı-Monrol Nuclear Products (Turkey)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nordion (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Advanced Accelerator Applications (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NTP Radioisotopes (South Africa)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Radiopharmaceuticals in Nuclear Medicine Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radiopharmaceuticals in Nuclear Medicine (Value)
      • 7.2.1. Global Radiopharmaceuticals in Nuclear Medicine by: Type (Value)
        • 7.2.1.1. Diagnostic Nuclear Medicine [PECT Radiopharmaceuticals, PET Radiopharmaceuticals]
        • 7.2.1.2. Therapeutic Nuclear Medicine [Alpha Emitters, Beta Emitters]
        • 7.2.1.3. Brachytherapy Isotopes [Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other]
      • 7.2.2. Global Radiopharmaceuticals in Nuclear Medicine by: Application (Value)
        • 7.2.2.1. SPECT Applications [Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications]
        • 7.2.2.2. PET Applications [Oncology, Cardiology, Neurology, Other PET Applications]
        • 7.2.2.3. Therapeutic Applications [Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other]
      • 7.2.3. Global Radiopharmaceuticals in Nuclear Medicine by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Research Institutes
        • 7.2.3.3. Others
      • 7.2.4. Global Radiopharmaceuticals in Nuclear Medicine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Radiopharmaceuticals in Nuclear Medicine (Price)
      • 7.3.1. Global Radiopharmaceuticals in Nuclear Medicine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiopharmaceuticals in Nuclear Medicine: by Type(USD Million)
  • Table 2. Radiopharmaceuticals in Nuclear Medicine Diagnostic Nuclear Medicine [PECT Radiopharmaceuticals, PET Radiopharmaceuticals] , by Region USD Million (2015-2020)
  • Table 3. Radiopharmaceuticals in Nuclear Medicine Therapeutic Nuclear Medicine [Alpha Emitters, Beta Emitters] , by Region USD Million (2015-2020)
  • Table 4. Radiopharmaceuticals in Nuclear Medicine Brachytherapy Isotopes [Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other] , by Region USD Million (2015-2020)
  • Table 5. Radiopharmaceuticals in Nuclear Medicine: by Application(USD Million)
  • Table 6. Radiopharmaceuticals in Nuclear Medicine SPECT Applications [Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications] , by Region USD Million (2015-2020)
  • Table 7. Radiopharmaceuticals in Nuclear Medicine PET Applications [Oncology, Cardiology, Neurology, Other PET Applications] , by Region USD Million (2015-2020)
  • Table 8. Radiopharmaceuticals in Nuclear Medicine Therapeutic Applications [Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other] , by Region USD Million (2015-2020)
  • Table 9. Radiopharmaceuticals in Nuclear Medicine: by End User(USD Million)
  • Table 10. Radiopharmaceuticals in Nuclear Medicine Hospitals , by Region USD Million (2015-2020)
  • Table 11. Radiopharmaceuticals in Nuclear Medicine Research Institutes , by Region USD Million (2015-2020)
  • Table 12. Radiopharmaceuticals in Nuclear Medicine Others , by Region USD Million (2015-2020)
  • Table 13. South America Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2015-2020)
  • Table 14. South America Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 15. South America Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 16. South America Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 17. Brazil Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 18. Brazil Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 19. Brazil Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 20. Argentina Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 21. Argentina Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 22. Argentina Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 23. Rest of South America Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 26. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 30. China Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 31. China Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 32. China Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 33. Japan Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 34. Japan Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 35. Japan Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 36. India Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 37. India Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 38. India Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 39. South Korea Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 40. South Korea Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 41. South Korea Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 42. Taiwan Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 43. Taiwan Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 44. Taiwan Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 45. Australia Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 46. Australia Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 47. Australia Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 51. Europe Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2015-2020)
  • Table 52. Europe Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 53. Europe Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 54. Europe Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 55. Germany Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 56. Germany Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 57. Germany Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 58. France Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 59. France Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 60. France Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 61. Italy Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 62. Italy Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 63. Italy Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 64. United Kingdom Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 67. Netherlands Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 68. Netherlands Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 69. Netherlands Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 70. Rest of Europe Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 73. MEA Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2015-2020)
  • Table 74. MEA Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 75. MEA Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 76. MEA Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 77. Middle East Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 78. Middle East Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 79. Middle East Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 80. Africa Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 81. Africa Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 82. Africa Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 83. North America Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2015-2020)
  • Table 84. North America Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 85. North America Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 86. North America Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 87. United States Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 88. United States Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 89. United States Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 90. Canada Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 91. Canada Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 92. Canada Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 93. Mexico Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2015-2020)
  • Table 94. Mexico Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2015-2020)
  • Table 95. Mexico Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2015-2020)
  • Table 96. Radiopharmaceuticals in Nuclear Medicine: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Radiopharmaceuticals in Nuclear Medicine: by Type(USD Million)
  • Table 108. Radiopharmaceuticals in Nuclear Medicine Diagnostic Nuclear Medicine [PECT Radiopharmaceuticals, PET Radiopharmaceuticals] , by Region USD Million (2021-2026)
  • Table 109. Radiopharmaceuticals in Nuclear Medicine Therapeutic Nuclear Medicine [Alpha Emitters, Beta Emitters] , by Region USD Million (2021-2026)
  • Table 110. Radiopharmaceuticals in Nuclear Medicine Brachytherapy Isotopes [Iodine-125, Palladium-103, Cesium-131, Iridium-192, Other] , by Region USD Million (2021-2026)
  • Table 111. Radiopharmaceuticals in Nuclear Medicine: by Application(USD Million)
  • Table 112. Radiopharmaceuticals in Nuclear Medicine SPECT Applications [Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications] , by Region USD Million (2021-2026)
  • Table 113. Radiopharmaceuticals in Nuclear Medicine PET Applications [Oncology, Cardiology, Neurology, Other PET Applications] , by Region USD Million (2021-2026)
  • Table 114. Radiopharmaceuticals in Nuclear Medicine Therapeutic Applications [Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other] , by Region USD Million (2021-2026)
  • Table 115. Radiopharmaceuticals in Nuclear Medicine: by End User(USD Million)
  • Table 116. Radiopharmaceuticals in Nuclear Medicine Hospitals , by Region USD Million (2021-2026)
  • Table 117. Radiopharmaceuticals in Nuclear Medicine Research Institutes , by Region USD Million (2021-2026)
  • Table 118. Radiopharmaceuticals in Nuclear Medicine Others , by Region USD Million (2021-2026)
  • Table 119. South America Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2021-2026)
  • Table 120. South America Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 121. South America Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 122. South America Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 123. Brazil Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 124. Brazil Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 125. Brazil Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 126. Argentina Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 127. Argentina Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 128. Argentina Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 129. Rest of South America Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 130. Rest of South America Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 131. Rest of South America Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 132. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2021-2026)
  • Table 133. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 134. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 135. Asia Pacific Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 136. China Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 137. China Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 138. China Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 139. Japan Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 140. Japan Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 141. Japan Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 142. India Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 143. India Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 144. India Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 145. South Korea Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 146. South Korea Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 147. South Korea Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 148. Taiwan Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 149. Taiwan Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 150. Taiwan Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 151. Australia Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 152. Australia Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 153. Australia Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 157. Europe Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2021-2026)
  • Table 158. Europe Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 159. Europe Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 160. Europe Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 161. Germany Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 162. Germany Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 163. Germany Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 164. France Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 165. France Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 166. France Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 167. Italy Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 168. Italy Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 169. Italy Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 170. United Kingdom Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 171. United Kingdom Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 172. United Kingdom Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 173. Netherlands Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 174. Netherlands Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 175. Netherlands Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 176. Rest of Europe Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 177. Rest of Europe Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 178. Rest of Europe Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 179. MEA Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2021-2026)
  • Table 180. MEA Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 181. MEA Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 182. MEA Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 183. Middle East Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 184. Middle East Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 185. Middle East Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 186. Africa Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 187. Africa Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 188. Africa Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 189. North America Radiopharmaceuticals in Nuclear Medicine, by Country USD Million (2021-2026)
  • Table 190. North America Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 191. North America Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 192. North America Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 193. United States Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 194. United States Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 195. United States Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 196. Canada Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 197. Canada Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 198. Canada Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 199. Mexico Radiopharmaceuticals in Nuclear Medicine, by Type USD Million (2021-2026)
  • Table 200. Mexico Radiopharmaceuticals in Nuclear Medicine, by Application USD Million (2021-2026)
  • Table 201. Mexico Radiopharmaceuticals in Nuclear Medicine, by End User USD Million (2021-2026)
  • Table 202. Radiopharmaceuticals in Nuclear Medicine: by Type(USD/Units)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiopharmaceuticals in Nuclear Medicine: by Type USD Million (2015-2020)
  • Figure 5. Global Radiopharmaceuticals in Nuclear Medicine: by Application USD Million (2015-2020)
  • Figure 6. Global Radiopharmaceuticals in Nuclear Medicine: by End User USD Million (2015-2020)
  • Figure 7. South America Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 8. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 9. Europe Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 10. MEA Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 11. North America Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 12. Global Radiopharmaceuticals in Nuclear Medicine: by Type USD/Units (2015-2020)
  • Figure 13. Global Radiopharmaceuticals in Nuclear Medicine share by Players 2020 (%)
  • Figure 14. Global Radiopharmaceuticals in Nuclear Medicine share by Players (Top 3) 2020(%)
  • Figure 15. Global Radiopharmaceuticals in Nuclear Medicine share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Cardinal Health (United States) Revenue, Net Income and Gross profit
  • Figure 18. Cardinal Health (United States) Revenue: by Geography 2020
  • Figure 19. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 20. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 21. Curium (France) Revenue, Net Income and Gross profit
  • Figure 22. Curium (France) Revenue: by Geography 2020
  • Figure 23. Lantheus Medical Imaging (United States) Revenue, Net Income and Gross profit
  • Figure 24. Lantheus Medical Imaging (United States) Revenue: by Geography 2020
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 27. Bracco Imaging (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Bracco Imaging (Italy) Revenue: by Geography 2020
  • Figure 29. Eczacıbaşı-Monrol Nuclear Products (Turkey) Revenue, Net Income and Gross profit
  • Figure 30. Eczacıbaşı-Monrol Nuclear Products (Turkey) Revenue: by Geography 2020
  • Figure 31. Nordion (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Nordion (Canada) Revenue: by Geography 2020
  • Figure 33. Advanced Accelerator Applications (France) Revenue, Net Income and Gross profit
  • Figure 34. Advanced Accelerator Applications (France) Revenue: by Geography 2020
  • Figure 35. NTP Radioisotopes (South Africa) Revenue, Net Income and Gross profit
  • Figure 36. NTP Radioisotopes (South Africa) Revenue: by Geography 2020
  • Figure 37. Global Radiopharmaceuticals in Nuclear Medicine: by Type USD Million (2021-2026)
  • Figure 38. Global Radiopharmaceuticals in Nuclear Medicine: by Application USD Million (2021-2026)
  • Figure 39. Global Radiopharmaceuticals in Nuclear Medicine: by End User USD Million (2021-2026)
  • Figure 40. South America Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 41. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 42. Europe Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 43. MEA Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 44. North America Radiopharmaceuticals in Nuclear Medicine Share (%), by Country
  • Figure 45. Global Radiopharmaceuticals in Nuclear Medicine: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Cardinal Health (United States)
  • GE Healthcare (United States)
  • Curium (France)
  • Lantheus Medical Imaging (United States)
  • Bayer AG (Germany)
  • Bracco Imaging (Italy)
  • Eczacıbaşı-Monrol Nuclear Products (Turkey)
  • Nordion (Canada)
  • Advanced Accelerator Applications (France)
  • NTP Radioisotopes (South Africa)
Additional players considered in the study are as follows:
JSC Isotope (Russia) , NorthStar Medical Radioisotopes (United States) , Eckert & Ziegler (Germany) , IBA Molecular Imaging , Progenics Pharmaceuticals, Inc. , NorthStar Medical Radioisotopes LLC , Life Molecular Imaging , Cardinal Health, Inc. , Eli Lilly and Company , Nihon Medi-Physics. Co. Ltd. , FUJIFILM Toyama Chemical Co., Ltd. , Jubilant Life Sciences Ltd. , Samyoung Unitech , DuChemBio, Inc. , Rotem Industries , Cambridge Isotope Laboratories, Inc.
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation